drugset
drugset / Trial / NCT03627052

A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

NCT03627052 ↗

Phase 2 Withdrawn Incyte Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of itacitinib in participants with moderate to severe ulcerative colitis (UC).

Timeline

Start
2018-09-20
Primary completion
2019-11-13
Completion
2019-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Itacitinib Small molecule — Oral

Indications

ulcerative colitis